Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma

American Journal of Clinical Pathology

Volumn 129, Issue 3, 2008, Pages 472-477

  Martini, Maurizio ^a   Hohaus, Stefan ^a   Petrucci, Giovanna ^a   Cenci, Tonia ^a   Pierconti, Francesco ^a   Massini, Giuseppina ^a   Teofili, Luciana ^a   Leone, Giuseppe ^a   Larocca, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hodgkin lymphoma; Prognosis; STAT5

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; STAT5 PROTEIN; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL FEATURE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REED STERNBERG CELL; RISK REDUCTION; TREATMENT FAILURE; ADOLESCENT; AGED; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; RADIOTHERAPY; SURVIVAL; TREATMENT OUTCOME; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; RADIOTHERAPY; REED-STERNBERG CELLS; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41649094211     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/63H1A83HRTBQ07DB     Document Type: Article

References (35)

1. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
2. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol. 2006;34:399-406.
3. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005;205:498-506.
4. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin's disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003;102:1019-1027.
5. Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin's and anaplastic large cell lymphoma. Blood. 2002;99:3398-3403.
6. Renné C, Willenbrock K, Küppers R, et al. Autocrine-and paracrine-activated receptor tyrosine kinases in classic Hodgkin's lymphoma. Blood. 2005;105:4051-4059.
7. Brauninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer. 2006;118:1853-1861.
8. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol. 2005;23:6379-6386.
9. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281-1283.
10. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol. 2006;6:602-612.
11. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.
12. Cochet O, Frelin C, Peyron JF, et al. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006;18:449-455.
13. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605-617.
14. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood. 1990;75:13-16.
15. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189:1939-1945.
16. Foss HD, Hummel M, Gottstein S, et al. Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. Am J Pathol. 1995;146:33-39.
17. Merz H, Houssiau FA, Orscheschek K, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood. 1991;78:1311-1317.
18. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
19. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999;274:22165-22169.
20. Kieslinger M, Woldman I, Moriggl R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14:232-244.
21. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259.
22. Chen H, Hutt-Fletcher L, Cao L, et al. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 2003;77:4139-4148.
23. Chen H, Lee JM, Zong Y, et al. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol. 2001;75:2929-2937.
24. Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004;22:2053-2060.
25. Li H, Zhang Y, Glass A, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 2005;11:5863-5868.
26. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res. 2005;11:2175-2179.
27. Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood. 2007;110:354-359.
28. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol. 2003;163:1687-1698.
29. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center- related B cells. Blood. 1998;92:1011-1019.
30. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679-2684.
31. Nosaka T, Kawashima T, Misawa K, et al. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754-4765.
32. Barash I. Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol. 2006;209:305-313.
33. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene. 2007;26:224-233.
34. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 2005;19:936-944.
35. Desrivieres S, Kunz C, Barash I, et al. The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia. 2006;111:75-87.